Lipocalin-type prostaglandin D synthase is not a biomarker of atherosclerotic manifestations

References

• Vanecek R. Atherosclerosis of the coronary arteries in five towns. Bull World Health Organ 1976;53:509–18.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525–38.
   PubMed Web of Science ®Google Scholar
• Diamond GA. A clinically relevant classification of chest discomfort. J Am Coll Cardiol 1983;1:574–5.
   PubMed Web of Science ®Google Scholar
• Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, Mickley H. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013;126:789–97.
   PubMed Web of Science ®Google Scholar
• Inoue T, Eguchi Y, Matsumoto T, Kijima Y, Kato Y, Ozaki Y, Waseda K, Oda H, Seiki K, Node K, Urade Y. Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. Atherosclerosis 2008; 201:385–91.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.
   PubMed Web of Science ®Google Scholar
• Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K, Staff AHA. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications: a statement for health professionals from the American Heart Association. Circulation 1996;94:1175–92.
   PubMed Web of Science ®Google Scholar
• Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998–2003.
   PubMed Web of Science ®Google Scholar
• Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686–96.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345:1022–9.
   PubMed Web of Science ®Google Scholar
• Cosin-Sales J, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, Cole D, Holt DW, Kaski JC. Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004;109:1724–8.
   PubMed Web of Science ®Google Scholar
• Cosin-Sales J, Kaski JC, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, Cole D, Holt DW. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J 2005;26:2093–8.
   PubMed Web of Science ®Google Scholar
• Coskun S, Atalar E, Ozturk E, Yavuz B, Ozer N, Goker H, Ovunc K, Aksoyek S, Kes S, Sivri B, Kirazli S, Ozmen F. Plasma osteopontin levels are elevated in non-ST-segment elevation acute coronary syndromes. J Natl Med Assoc 2006;98:1746–50.
   PubMed Web of Science ®Google Scholar
• Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, Raffa S, D'anneo G, Luca F, Mioni C, Arrigo F, Squadrito F. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 2005;109:389–95.
   PubMed Web of Science ®Google Scholar
• Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192–4.
   PubMed Web of Science ®Google Scholar
• Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003;170:333–7.
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Rizzello V, Calabro A, Gallotta M, Martini G, Quatrini I, Campagna MS, Franci B, Nuti R. Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number. Clin Chim Acta 2008; 391:74–9.
   PubMed Web of Science ®Google Scholar
• Ren MY, Sui SJ, Zhang Y, Xu FY, Xu XQ, Zhao JJ, Du YM, Liu WH. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol 2008;63:615–22.
   PubMed Web of Science ®Google Scholar
• Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003;88:1024–8.
   PubMed Web of Science ®Google Scholar
• Diederichsen AC, Sand NP, Norgaard B, Lambrechtsen J, Jensen JM, Munkholm H, Aziz A, Gerke O, Egstrup K, Larsen ML, Petersen H, Hoilund-Carlsen PF, Mickley H. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. Eur J Prev Cardiol 2012;19:558–64.
   PubMed Web of Science ®Google Scholar
• Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32.
   PubMed Web of Science ®Google Scholar
• Agatston AS, Janowitz WR, Kaplan G, Gasso J, Hildner F, Viamonte M Jr. Ultrafast computed tomography-detected coronary calcium reflects the angiographic extent of coronary arterial atherosclerosis. Am J Cardiol 1994;74:1272–4.
   PubMed Web of Science ®Google Scholar
• Cangemi C, Skov V, Poulsen MK, Funder J, Twal WO, Gall MA, Hjortdal V, Jespersen ML, Kruse TA, Aagard J, Parving HH, Knudsen S, Hoilund-Carlsen PF, Rossing P, Henriksen JE, Argraves WS, Rasmussen LM. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem 2011;57:1556–65.
   PubMed Web of Science ®Google Scholar
• Skov V, Knudsen S, Olesen M, Hansen ML, Rasmussen LM. Global gene expression profiling displays a network of dysregulated genes in non-atherosclerotic arterial tissue from patients with type 2 diabetes. Cardiovasc Diabetol 2012;11:15.
   PubMed Web of Science ®Google Scholar
• Miwa Y, Oda H, Shiina Y, Shikata K, Tsushima M, Nakano S, Maruyama T, Kyotani S, Eguchi N, Urade Y, Takahashi-Yanaga F, Morimoto S, Sasaguri T. Association of serum lipocalin-type prostaglandin D synthase levels with subclinical atherosclerosis in untreated asymptomatic subjects. Hypertens Res 2008;31:1931–9.
   PubMed Web of Science ®Google Scholar
• Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Muller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damas JK, Froland SS, Hansson GK, Halvorsen B, Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006;26:857–63.
   PubMed Web of Science ®Google Scholar
• Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32: 681–6.
   PubMed Web of Science ®Google Scholar
• Pedersen ER, Ueland T, Seifert R, Aukrust P, Schartum-Hansen H, Ebbing M, Bleie O, Igland J, Svingen G, Nordrehaug JE, Nygard O. Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. Atherosclerosis 2010;212:644–9.
   PubMed Web of Science ®Google Scholar
• Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010;8:1170–5.
   PubMed Web of Science ®Google Scholar
• Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008;159: 603–8.
   PubMed Web of Science ®Google Scholar
• Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627–33.
   PubMed Web of Science ®Google Scholar
• Iversen K, Teisner A, Dalager S, Olsen KE, Floridon C, Teisner B. Pregnancy associated plasma protein-A (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque. Clin Biochem 2011;44:312–8.
   PubMed Web of Science ®Google Scholar
• Terkelsen CJ, Oxvig C, Norgaard BL, Glerup S, Poulsen TS, Lassen JF, Moller HJ, Thuesen L, Falk E, Nielsen TT, Andersen HR. Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration. Am J Cardiol 2009; 103:29–35.
   PubMed Web of Science ®Google Scholar
• Tertti R, Wittfooth S, Porela P, Airaksinen KE, Metsarinne K, Pettersson K. Intravenous administration of low molecular weight and unfractionated heparin elicits a rapid increase in serum pregnancy-associated plasma protein A. Clin Chem 2009;55:1214–7.
   PubMed Web of Science ®Google Scholar
• Rubin J, Chang HJ, Nasir K, Blumenthal RS, Blaha MJ, Choi EK, Chang SA, Yoon YE, Chun EJ, Choi SI, Agatston AS, Rivera JJ. Association between high-sensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary computed tomography angiography in an asymptomatic population. Circ Cardiovasc Imaging 2011;4:201–9.
   PubMed Web of Science ®Google Scholar
• Shun-Shin M, Francis DP. Why are some studies of cardiovascular markers unreliable?The role of measurement variability and what an aspiring clinician scientist can do before it is too late. Prog Cardiovasc Dis 2012;55:14–24.
   Google Scholar
• Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113: 2335–62.
   PubMed Web of Science ®Google Scholar
• Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006;48:1–11.
   PubMed Web of Science ®Google Scholar
• Erbel R, Mohlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, Dragano N, Gronemeyer D, Seibel R, Kalsch H, Brocker-Preuss M, Mann K, Siegrist J, Jockel KH. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol 2010;56:1397–406.
   PubMed Web of Science ®Google Scholar